Aggrastat To Zocor

A-phase of the Aggrastat to Zocor (A to Z) study Comparison of the

File Format: Microsoft Powerpoint - View as HTMLAGGRASTAT to ZOCOR (A to Z) Trial Comparison of the safety and efficacy of unfractionated heparin versus enoxaparin in combination with tirofiban and.

Journal of the American College of Cardiology : Myocardial

The Aggrastat to Zocor (A to Z) trial. This late-breaking randomized clinical trial was sponsored by Merck and Company. It was presented by Dr. Michael.

Myocardial infarction and ischemia -- Shah 42 (2): 375 -- Journal

Immediate reduction in acuteEffect of glucose, insulin,The Aggrastat to ZocorEfficacy of a novelRegional angiogenesis with.

Meta-Analysis of Trials Comparing Intensive v. Moderate Statin

[2,3] However, 2 trials, the A-to-Z (Aggrastat to Zocor) and IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering),[4,5] had.

Angina: Free Medical and Health Information on Angina Treatment

Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or.

Clinical Relevance of C-Reactive Protein During Follow-Up of

Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial. David A. Morrow, MD.

Issue Highlights -- 114 (4): 257 -- Circulation

CLINICAL RELEVANCE OF C-REACTIVE PROTEIN DURING FOLLOW-UP OF PATIENTS WITH ACUTE CORONARY SYNDROMES IN THE AGGRASTAT-TO-ZOCOR TRIAL, by Morrow et al.

A TO Z STUDY ANNOUNCED BY WORLD-RENOWNED TEAM OF CARDIOLOGISTS AT

Barcelona, Spain - A team of world-renowned cardiologists today announced the start of the "A To Z" (Aggrastat To Zocor) Study, a major new clinical trial.

AHA - Additional Content - 507593

Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial.

A to Z -- Aggrastat to Zocor (TIMI 21) and PRINCESS -- Prevention

More evidence comes from 2 trials showing that early initiation of statin therapy following an acute coronary syndrome event reduces major cardiovascular.